Sangamo Therapeutics misses top-line and bottom-line estimates; reaffirms FY25 outlook Sangamo Therapeutics misses top-line and bottom-line estimates; reaffirms FY25 outlook Post ContentsgmoRead More You might also be interested in reading 6 Questions for Wes Levitt of Theta Labs. May 13, 2025 In Mainstream ← Previous post Next post →